Shangjun Lin carefully places a tiny drop of fluid onto a palm-sized chip, no bigger than a postage stamp, etched with microscopic patterns of gold. In Zhuhai, China, Lin and a team of researchers are pushing the boundaries of how quickly and precisely we can detect the invisible signs of brain injury. Their innovation—a metasurface biosensor—could transform how doctors diagnose traumatic brain injury (TBI), a condition that affects millions worldwide and often goes undetected until it’s too late. Every second counts after a head injury, yet current diagnostic methods rely on slow, lab-intensive processes or costly CT scans. This new technology promises something different: ultrasensitive detection from just a small sample, potentially as simple as a finger prick.
Led by Guangyuan Li of the Beijing Institute of Technology, Zhuhai, and Yunhui Liu from the Shenzhen Institute of Technology, CAS, the team has engineered a biosensor capable of detecting TBI biomarkers at levels as low as one femtogram per milliliter—about a quadrillionth of a gram in a single milliliter of fluid. That’s like finding a single grain of sand in an Olympic-sized swimming pool. The sensor works by coating a nanostructured gold surface with antibodies that bind to two key TBI biomarkers: glial fibrillary acidic protein (GFAP) and S100 calcium-binding protein β (S100β). When these proteins attach, they shift the way light reflects off the chip, producing a measurable signal so precise it can detect even the faintest trace.
The heart of the device is its corrugated gold metasurface, fabricated using high-precision nanotechnology to minimize optical loss and maximize sensitivity. With a high-quality (high-Q) resonance, the sensor produces an extremely narrow dip in the light spectrum—so narrow that even minuscule changes from biomarker binding are easy to spot. The team tested the sensors with concentrations ranging from 1 fg/mL to 100 ng/mL and found clear, reproducible responses, with minimal interference from non-target proteins like H-FABP and UCH-L1. This specificity is crucial for clinical reliability.
While the fabrication process remains expensive, the researchers emphasize its scalability and are actively working to reduce costs. Next steps include refining fluid handling, packaging, and validating the system with real patient samples. If successful, the technology could be deployed in ambulances, rural clinics, sports fields, or emergency rooms—anywhere rapid, accurate diagnosis is critical.
"If developed into a point-of-care format, this technology could help provide faster and more accurate answers after brain injury—perhaps using just a finger prick," said Liu. That vision—a future where a life-changing diagnosis takes minutes, not hours—now feels closer than ever.